Table 2 |
|||||
|
Combination of GC-marker immunoreactivity in the series of FL |
|||||
|
Triple-positive N.cases (%) |
Double-positive N.cases (%) |
Single-positive N.cases (%) |
|||
|
|
|||||
|
Groups (N.cases) |
HGAL/BCL6/CD10 |
HGAL/BCL6 |
HGAL/CD10 |
BCL6 |
HGAL |
|
|
|||||
|
In situ FL (6) |
3 (50%) |
- |
3 (50%) |
- |
- |
|
|
|||||
|
Nodal FL (61) |
53 (87.1%) |
4 (6.5%) |
2 (3.2%) |
2 (3.2%) |
- |
|
|
|||||
|
FL+LBCL (10) |
8 (80%) |
1 (10%) |
- |
- |
1 (10%) |
|
|
|||||
|
CFL (5) |
5 (100%) |
- |
- |
- |
- |
|
|
|||||
|
Total (82) |
69 (84.2%) |
5 (6.1%) |
5 (6.1%) |
2 (2.4%) |
1 (1.2%) |
|
|
|||||
|
Goteri et al. Diagnostic Pathology 2011 6:97 doi:10.1186/1746-1596-6-97 |
|||||
